Drugs / BRILANESTRANT
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02802670 | May → Jun 2016 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02722018 | Jan → Sep 2016 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02621957 | Dec 2015 → Feb 2016 | breast cancer | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01823835 | Dec 2014 → Mar 2020 | breast cancer | Genentech, Inc. | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02569801 | Dec 2015 → Feb 2020 | breast cancer | Genentech, Inc. | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BRILANESTRANT | ChEMBL registry synonym — accepted as the source's own label CHEMBL3581693 ↗ |
| Known as | ARN-810 | “PURPOSE: GDC-0810 (ARN-810) is a novel, non-steroidal, orally bioavailable, selective estrogen receptor degrader (SERD) that potentially inhibits ligand-dependent and...” PMID 36401732 ↗ Nov 2022 |
| Known as | GDC-0810 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02802670 ↗ |
| Known as | RG-6046 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3581693 ↗ |
| Action | Deplete | “Estrogen receptor degrader” CHEMBL3581693 ↗ |
| Modality | Small molecule | — CHEMBL3581693 ↗ |
| Route | Oral | “GDC-0810 administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).” NCT01823835 ↗ |
| Target | ESR1 | “Estrogen receptor degrader” CHEMBL3581693 ↗ |